Company
Ginkgo Bioworks Holdings, Inc.
Headquarters: Boston, MA, United States
Employees: 495
CEO: Dr. Jason Kelly
Ginkgo Bioworks Holdings, Inc. Categories
United States Healthcare BiotechnologyUnited States Healthcare United States Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Ginkgo Bioworks Holdings, Inc. develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to advance treatments for orphan and rare diseases. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is based in Boston, Massachusetts.
Financials
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | $251.5 M |
| EBITDA | $-662,280,000 |
| Gross Profit TTM | $197.4 M |
| Profit Margin | 78.52% |
| Operating Margin | -515.53% |
| Quarterly Revenue Growth | -64.60% |
Stocks & Indices
Ginkgo Bioworks Holdings, Inc. has the following listings and related stock indices.
Stock: NYSE: DNA wb_incandescent